https://www.scientificarchives.com/journal/journal-of-cellular-immunology

Journal of Cellular Immunology Review Article

Targeting the High Affinity Receptor, FcγRI, in Autoimmune Disease, Neuropathy, and Cancer

Tosca Holtrop[1], Kevin Budding[1], Arianne M. Brandsma[2], Jeanette H.W. Leusen[1*]

[1]Immunotherapy Laboratory, Center for Translational Immunology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands

[2]Princess Máxima Center for Pediatric Oncology and Oncode Institute, Heidelberglaan 25, 3584CS Utrecht, The Netherlands

*Correspondence should be addressed to Jeanette H.W. Leusen; jleusen@umcutrecht.nl

Received date: June 06, 2021, **Accepted date:** August 13, 2021

Abstract

The Fc gamma receptor I (FcγRI or CD64) is the only human Fc receptor with a high affinity for monomeric IgG. It plays a crucial role in immunity, as it mediates cellular effector functions of antibodies including phagocytosis, antigen presentation, and cytokine production. FcγRI is constitutively saturated with monomeric IgG and this feeds the dogma that it has no role in immune responses. However, recent findings have implicated a role for FcγRI in various autoimmune disorders, neuropathies, and antibody therapy in tumor models. By a process known as 'inside-out' signaling, stimulation of myeloid cells with cytokines such as tumor necrosis factor alpha (TNF-α) and interferon-gamma (IFN-γ) enhances FcγRI binding to immune complexes (ICs), including antibody-opsonized pathogens or tumor cells.

This review focuses on the current knowledge on interaction of FcγRI with IgG and ICs and the effect of inside-out signaling on FcγRI functioning. Additionally, this review will address potential clinical applications of targeting FcγRI, and the tools that can be used to overcome IC-mediated autoimmune diseases on the one hand, and to enhance antibody-based anti-cancer therapy on the other.

Keywords: CD64, Inside-out signaling, Therapeutic antibodies, Blocking antibodies, Autoimmunity, Neuropathy, Cancer, Immune complexes

Abbreviations: ADCC/ADCP: Antibody-Dependent Cellular Cytotoxicity/Phagocytosis; AIA: Antigen-Induced Arthritis; ATG: Anti-thymocyte Globulin; bsAbs: Bispecific Antibodies; CDC: Complement-Dependent Cytotoxicity; CIA: Collagen-Induced Arthritis; CY: Cytoplasmic; DRG: Dorsal Root Ganglion; EC: Extracellular Domain; Fab: Antigen-binding Fragment; FcγR: Fc gamma Receptor; G-CSF: Granulocyte Colony-Stimulating Factor; IC: Immune Complex; INF-γ: Interferon gamma; ITAM/ITIM: Immunoreceptor Tyrosine-based Activation/Inhibition Motif; ITP: Immune Thrombocytopenia; IVIg: Intravenous Immunoglobulin; LN: Lupus Nephritis; mAb: Monoclonal Antibody; MCP-1: Monocyte Chemoattractant Protein 1; NK: Natural Killer cell; PMN: Polymorphonuclear; PP1: Protein Phosphatase 1; RA: Rheumatoid Arthritis; SLE: Systemic Lupus Erythematosus; TNF-α: Tumor Necrosis Factor Alpha

Introduction

Fc gamma receptors (FcγRs) are transmembrane proteins that bind to the Fc tail of IgG antibodies. They are required for cellular effector functions of antibodies, including direct neutralization of pathogens, recruitment of the complement system to directly lyse pathogens or infected cells, and cellular effector functions including phagocytosis and antibody-dependent cellular cytotoxicity/phagocytosis (ADCC/ADCP) [1,2]. As many FcRs are mostly expressed on innate immune cells [3], they serve as a vital connection between the cellular and humoral parts of the immune system, connecting antigen-specific interactions of antibodies to nonspecific effector mechanisms of FcR-bearing cells.

FcγR activation is tightly regulated to prevent immune responses by non-antigen-bound antibodies, or in the

absence of other 'danger signals' (e.g. cytokines). For example, most FcγRs recognize IgG with low affinity, but can bind immune complexes (ICs), like opsonized pathogens, with high avidity [4]. FcγRI is the only FcγR with a high affinity for IgG. Because of its high affinity, FcγRI is constitutively saturated with monomeric IgG, even after isolation or extravasation of immune cells, but it does not lead to intracellular signaling and subsequent effector functions [1]. This led to the dogma that this receptor played no role in immune responses, resulting in FcγRI to be much less studied than the low affinity FcγRs. However, several studies demonstrated that FcγRI does play a significant part in inflammation, autoimmunity and neuropathy, as well in antibody-therapy in tumor models [5-9].

FcγRI saturated with pre-bound IgG is able to effectively bind ICs after cytokine stimulation [10]. This process is called 'inside-out signaling', as the ligand binding capacity of the receptor is rapidly enhanced after intracellular signaling without affecting the receptor expression. This process is also described for integrins [11], as well as for FcαRI and FcγRIIa [12,13]. Stimulation with cytokines strongly enhances IC binding, resulting in stronger cellular effector functions such as ADCC [10,14]. Moreover, therapeutic antibodies that bind to FcγRI can also benefit from cytokine stimulation, leading to improved tumor killing [12,15,16].

In this review, we will discuss FcγRI interactions with IgG and ICs, as well as how to enhance FcγRI cellular effector functions via inside-out signaling. Additionally, this review will focus on how therapeutic antibodies targeting FcγRI, possibly in combination with inside-out signaling, can be turned into novel therapeutic strategies to treat human autoimmune, infectious, and malignant diseases.

The High Affinity IgG Receptor FcγRI

The affinities and specificities for the different IgG subclasses vary considerably within the FcγR family (e.g. FcγRI, FcγRIIa, FcγRIIb and FcγRIII). Only FcγRI binds with high affinity to human IgG, and binds exclusively to IgG1, IgG3 and IgG4, not IgG2 [4,17]. This high affinity binding is cross-species, as also rabbit IgG and mouse IgG2a and IgG2c can bind to human FcγRI with high affinity [18-20] Likewise, mouse FcγRI is also a high affinity receptor for mouse IgG2a, which is a functional homologue of human IgG1 [21], as well as for human and rabbit IgG [19,22].

FcγRI consists of three extracellular domains, a transmembrane part, and an intracellular tail (FcγRI-CY) (Figure 1A). Extracellular domain one (EC1) and two (EC2) are homologous to those found in other FcγRs, but EC3, which bridges EC2 with the transmembrane part of the receptor, is unique to FcγRI [23]. The transmembrane



Figure 1: Schematic representation of FcγRI and FcγRI functions. **(A)** Schematic representation of FcγRI with three extracellular domains; EC1, EC2 and EC3, the transmembrane part and intracellular tail (FcγRI-CY). The γ-chain and α-chain are responsible for different actions of the receptor. **(B)** FcγRI functions are regulated on multiple levels. **(1)** Interaction of FcγRI with monomeric IgG leads to rapid internalization and recycling of the receptor-IgG complex to the plasma membrane. **(2)** Crosslinking of FcγRI by ICs induces immunoreceptor tyrosine-based activation motif (ITAM) signaling via FcRγ and internalization and degradation of the antigen-receptor complex in the lysosome. The degraded peptides can be presented on MHC class I (MHC I) or MHC class II (MHC II), which leads to T cell activation.

part is responsible for FcR γ-chain association, and the α-chain of the receptor has an intracellular tail [9]. The interaction between IgG and FcγRI lies within two binding sites of the EC2 domain (Figure 2A). The binding of the Fc-tail to these two sites occurs in an asymmetric manner: to engage the receptor, the Fc-tail must use a different set of residues from each chain of the homodimer [17]. Binding to site 1 is governed by the insertion of Leucine235 (Figure 2B), while binding to site 2 involves a relatively flat interaction surface and does not involve a local conformational change (Figure 2C). Leucine235, as well as the critical residues 233 and 234, on IgG-Fc has been identified to be crucial for binding to FcγRI [17,24]. These critical residues are changed in IgG2, explaining why this antibody cannot bind to FcγRI [17].

It was proposed that the high affinity of FcγRI was due to the extra EC3 domain [23], which was supported by studies that switched the extracellular domains of FcγRI with extracellular domains of low affinity FcγRs [23-25]. However, the crystal structure of FcγRI indicated that EC3 is located distal from the IgG binding site in EC2 [26]. As a result, EC3 is unlikely to come into direct contact with IgG, although it may promote high affinity binding by stabilizing the IgG binding conformation or extending the receptor into the extracellular space [17,26]. Also, studies on the affinity of recombinant FcγRI lacking EC3 show that the effect of EC3 on high affinity binding is relatively minor [23].

Several studies now show that the EC2 domain converts the high affinity binding of FcγRI [17,26]. Because of a deletion of one amino acid, the FG-loop, which is present in one of the two binding sites of EC2, is shorter in FcγRI than in the other FcγRs. This deletion may reduce steric hindrance for IgG. This deletion also revealed a unique hydrophobic pocket in EC2 of FcγRI, which perfectly suited the residue Leu235 of the Fc-tail, explaining the



Figure 2: Schematic representation of Fc-FcγRI interaction. **(A)** Extracellular domains EC1, EC2 and EC3 are depicted in cyan, purple and blue, respectively. The Fc-tail of the antibody is depicted in grey. CH stands for constant heavy chain, CL for constant light chain, VL for variable light chain and VH for variable heavy chain. Orange dashed boxes indicate binding sites 1 and 2. **(B)** Detailed depiction of binding site 1 (FcγRI and Fc-chain). The surface of EC2 is shown in purple and the surface of EC1 in cyan. The residues of the Fc-chain involved in the interaction of FcγRI are represented with lines (grey=Fc-chain, yellow= carbon, red=oxygen and blue=nitrogen). The blue dashed lined represents the hydrophobic pocket where Leu235 can bind. **(C)** Detailed depiction of binding site 2. The same color scheme as in **(B)** is used. Here the interaction surface lies relatively flat. Adapted from Kiyoshi et al [17].

high affinity [17] (Figure 2B). Additionally, the FG-loop within EC2 has been demonstrated to interact with glycans on the Fc-tail of IgG, which is unique for FcγRI [27].

Binding of monomeric IgG to FcγRI does not lead to intracellular signaling and subsequent FcγRI activation, but it does facilitate receptor-mediated endocytosis and recycling (Figure 1B) [23,28,29]. Monomeric IgG binding to FcγRI likely creates a threshold for IC, allowing only large ICs or many smaller complexes to displace monomeric IgG. Studies with FcγRI knock-out mice, as well as biochemical studies investigating IC binding, show that FcγRI does significantly bind and respond to ICs of various sizes [5,20,30]. FcγRI effector responses include bacterial clearance, inflammation, anaphylaxis, endocytosis, phagocytosis, antigen presentation, release of B-cell stimulating factors, and anti-tumor responses [5,6,20,31].

FcγRI Expression and Signaling

FcγRI is constitutively expressed on most myeloid cells, including macrophages, monocytes, and dendritic cells, and can be induced by cytokines on neutrophils, mast cells, and eosinophils [3]. FcγRI is also inducible on endothelial cells [32] and neurons [33]. Besides FcγRI, effector cells express other FcγRs that can bind to ICs as well.

FcγRI expression can be upregulated by cytokines. For example, FcγRI expression on dendritic cells and monocytes can be increased by pro-inflammatory cytokines such as tumor necrosis factor alpha (TNF-α) and interferon gamma (IFN-γ) [10,34]. Anti-inflammatory cytokines, like transforming growth factor beta (TGF-β), IL-4 and IL-10 can decrease FcγRI expression while increasing expression of the inhibitory FcγRIIb. By altering expression levels of FcγRI, the immune response can be regulated, as an increased number of receptors can bind more ligand.

FcγRI signals via the immunoreceptor tyrosine-based activation motif (ITAM), which is located on the γ-chain (Figure 1). The ligand-binding domain of FcγRI can interact with ICs, such as antibody-opsonized pathogens or tumor cells [20,30,35]. After cross-linking the ligand-binding EC2 by ICs, the tyrosine residues of the ITAM can be phosphorylated by kinases of the SRC family [1]. These phosphotyrosines serve as a docking site for SYK kinases, which bind via their SH2 domains and are activated upon binding [5]. SYK activation results in the activation of the RAS-MAPK pathway, increased intracellular calcium levels and eventually activation of NF-κB transcription factors through induction of multiple downstream targets [36]. These signals activate immune cells, resulting in phagocytosis, oxidative burst, and cytokine release. However, cross-linking of the inhibitory FcγRIIb causes LYN to phosphorylate the immunoreceptor tyrosine-based inhibitory motif (ITIM), which recruits and activates the SH2-containing phosphatases SHIP and SHP1 [37,38]. Subsequently, the kinases downstream of ITAM signaling will be dephosphorylated by these phosphatases. This can suppress FcγRI effector functions by balancing the activating signaling cascades.

Immunomodulatory effects are mainly regulated via the single inhibitory receptor, FcγRIIb. However, recent studies have shown that the activating FcγRI and FcγRIIa can also produce inhibitory signals [39-42]. FcγRI engagement along with phagocytic signaling may facilitate inhibitory functions, including secretion of IL-10, reducing pro-inflammatory cytokine production and reducing T-cell proliferation [43]. Upon IC binding to FcγRI, it is possible that IL-10 secretion affects the macrophage response, leading to both augmenting FcγRI and altering the status of the macrophage and subsequently the outcome of the FcγRI engagement. IC-mediated signaling by FcγRI can also inhibit IFN-γ signaling events [44]. This points to an IC-mediated inhibition of IFN-γ signaling that involves the ITAM-containing FcγRI as well as the ITIM-dependent phosphatase SHP-1, thereby effectively suppressing STAT1 phosphorylation. Studies using various FcR-blocking antibodies in FcR γ-chain knockout mice and FcγRI$^{-/-}$ mice confirmed that the FcγRI mediates these suppressive effects [5,6,45]. However, more research is needed to better understand the possible inhibitory signals of FcγRI.

Inside-out Signaling on FcγRI Regulation

Since triggering of FcR leads to strong effector responses and potential cytokine storms, these receptors need to be tightly regulated. An example of regulation is that only clusters of immunoglobulins can activate low affinity receptors. For FcγRI this is regulated differently; the receptor function is always blocked by its ligand IgG, and the receptor can only be activated with a proper second signal. FcγRI, like integrins, is under 'inside-out' signaling, which means that binding of a cytokine to a cytokine receptor can change FcγRI so that it can bind and respond to ICs even when saturated with monomeric IgG [10,12,14] (Figure 3.I). TNF-α and IFN-γ, can rapidly enhance the IC binding capacity and subsequent effector functions, without altering FcγRI surface expression levels and affecting affinity for monomeric IgG [10].

Two mechanisms have been proposed by which cytokine stimulation enhances the binding capacity of FcγRI: increased clustering of the receptor and/or a conformational change of FcγRI. First, FcγRI, which is normally found in lipid rafts [46], becomes more clustered in the plasma membrane in response to cytokine stimulation, increasing its avidity [23,47]. This was demonstrated by super resolution imaging, which revealed that cytokines influence the cluster size of FcγRI in Ba/F3-



Figure 3: Role of FcγRI in autoimmune diseases and possible clinical applications for targeting FcγRI. Numbers depict autoimmune diseases and Roman numerals the possible intervention techniques. **(1)** In SLE, IgG autoantibodies are produced against self-antigens, which opsonize late apoptotic cells. Blocking FcγRI (not depicted) increases phagocytosis of apoptotic cells [62]. **(2)** ICs, formed by autoantibodies and self-antigens, reside in the kidney, causing the infiltration of FcγRI-expressing monocytes and macrophages, which release pro-inflammatory cytokines and chemokines, leading to inflammation and subsequently LN. **(3)** In ITP, IgG autoantibody-coated platelets get cleared by FcγRI-expressing macrophages and blocking FcγRI reduced clearance by 50% [20] (not depicted). **(4)** In atopic dermatitis, FcγRI expression is increased on M1 macrophages, making them readily bind to the increased total and antigen-specific serum IgG4 [60]. FcγRI-targeted immunotoxins alters the polarization towards M2 phenotype [59]. **(5)** In RA, IgG autoantibody ICs can bind macrophages and neutrophils causing the release of pro-inflammatory cytokines which increase inflammation and RA morbidity. The IgG-ICs also translocate to the joints, causing further inflammation. They can also directly bind to osteoclasts. Capturing the IgG-ICs with recombinant soluble FcγRs (III) reduces cartilage degradation (not depicted) [73,74]. **(6)** Activation of FcγRI on DRG neurons caused increased neuron excitability and subsequent pain. Blocking the receptor relieved pain in mice [75,76]. **(I)** Cytokines cause inside-out signaling, leading to enhanced clustering of FcγRI in the membrane. Cytokines also regulate expression of FcγRI by inducing transfer of intracellular FcγRI to the plasma membrane as well as de novo expression. **(II)** bsAbs can be engineered to bind FcγRI-expressing target cells and a tumor-target, thereby inducing tumor-killing [77-79]. **(III)** Recombinant soluble FcγR can 'capture' circulating ICs. SLE: Systemic Lupus Erythematous; LN: Lupus Nephritis; ITP: Immune Thrombocytopenic Purpura; RA: Rheumatoid Arthritis; bsAbs: bispecific antibodies.

FcγRI cells [14]. This process is dependent on an intact actin cytoskeleton, and the involvement of the serine/threonine phosphatase PP1 (protein phosphatase 1), while the phosphorylation of FcγRI-CY itself is unaffected [14]. This in contrast to FcγRI crosslinking (outside-in signaling), where all four serines in the CY domain of FcγRI need to be dephosphorylated upon crosslinking to lead to phagocytosis [48]. Interestingly, okadaic acid, which is a phosphatase inhibitor of PP2 at low concentrations and PP1 at higher concentrations, prevents the dephosporylation of these serines in outside-in signaling, while it does not directly influence FcγRI phosphorylation in inside-out signaling [14,49]. Second, a change in FcγRI conformation may increase its binding capacity and affinity for IC. In outside-in signaling, dephosphorylation changes the charge of FcγRI-CY, resulting in a conformational change. This is accompanied by a conformational change in the transmembrane domain and, ultimately, in one or more extracellular domains [50]. FcγRI crystallization revealed that when IgG binds, the EC1 and EC2 domains rotate 19

degrees with respect to the EC3 domain [10]. This rotation could lead to a conformation change of the receptor that alters the affinity of FcγRI for ICs. If the rotation tilts the EC2 domain, there may be more space for an IC to bind to multiple FcγRI molecules. Future research may reveal if increased FcγRI clustering after cytokine stimulation correlates with a conformational change of the receptor.

The implications of FcR inside-out signaling in the treatment of patients with therapeutic antibodies is still under investigation. Activating inside-out signaling could be advantageous to increase the clinical efficacy of therapeutic antibodies. However, FcRs also play a role in the clearance of target-antibody complexes via endocytosis and subsequent degradation in the lysosomal compartment [12]. In these cases, it might be beneficial to inhibit FcRs with antagonistic cytokines to preserve sufficient therapeutic doses of the antibodies, ultimately allowing for lower antibody administration or maintenance doses [51]. Taking advantage of FcR inside-out signaling will ultimately depend on the requirements of the effector cells needed, which FcR they express and the mode(s) of action of the therapeutic antibodies [51]. This complexity should be taken into account to optimize the therapeutic effectiveness of existing and new antibodies.

Clinical Applications of FcγRI

Antibody therapy

There is increasing evidence that FcRs play a significant role in the induction and maintenance of pathological inflammatory responses induced by ICs, especially autoantibody ICs. The balance between 'activating' and 'inhibitory' roles of FcRs modulates FcR-dependent antibody effector responses in normal immunity [52]. Deviation towards activating functions of FcγRs, as seen in some autoimmune diseases, will reduce the threshold for IC-mediated activation of inflammatory cells, leading to inflammation and tissue damage [2,52]. Murine FcγRI has been implicated in a number of monoclonal antibody (mAb)-mediated disease models [6,7,53] and mAb therapy showed the potency of FcγRI in eliciting mAb-mediated effector responses (Figure 3) [35].

Antibodies are of interest in immunotherapy due to their high target specificity. Binding of specific antigens is possible through the variable region located in the antigen-binding fragment (Fab), while the non-variable Fc tail can simultaneously bind to FcγRI. The Fab domain of FcγRI can interact with ICs, such as antibody-opsonized pathogens or tumor cells, resulting in antigen internalization or blockade of signal transduction pathways [20,30,35]. Strategies for targeting FcγRI, inducing direct Fc blocking, and overcoming IC-mediated autoimmune disorders, are all part of the advancement of therapeutics for the treatment of inflammation [5,54].

Autoimmune diseases

The pathogenic effects of systemic autoimmune diseases are thought to be triggered by the development of autoantibodies and subsequent IC deposition in tissues [55]. Autoantibodies cause inflammation in antibody-dependent autoimmunity syndromes including immune thrombocytopenia purpura (ITP), systemic lupus erythematosus (SLE), and arthritis by binding to FcγRs [55-58]. In several chronic inflammatory diseases increased expression of FcγRI on M1 macrophages has been observed. Targeting FcγRI with mAbs that block the receptor showed promising results in inducing elimination of the disease-causing M1 macrophage population, while leaving the M2 anti-inflammatory population intact, even though both express FcγRI [59].

Atopic dermatitis is an allergic skin disease characterized by increased levels of total and antigen-specific serum IgE and IgG4 [60]. In both the acute and chronically inflamed skin, FcγRI expression levels are increased, which probably results from upregulation of the receptors on macrophages [60]. *In vitro* and *in vivo* studies showed that FcγRI-targeted immunotoxins can effectively eliminate murine and human M1 macrophages with high specificity [59]. This elimination alters the micro-environment, favoring polarization towards the M2 phenotype. FcγRI-targeted therapeutics can thus be a powerful tool for both identifying M1 macrophages *in vivo* and reversing M1-associated chronic disease (Figure 3.4).

ITP is an autoimmune disease characterized by low platelet counts caused by autoantibody-mediated clearance of platelets, which results in easy bruising and increased bleeding. Here, FcγRI-expressing macrophages seem to play an essential role in this chronic disease, where they contribute to platelet clearance (Figure 3.3). Using an anti-FcγRI antibody, platelet clearance could be reduced by 50% [20]. In mouse models, ITP could only be prevented by combining blocking antibodies for FcγRI and FcγRIV, the latter being a murine specific Fc-receptor. Nonetheless, the use of an anti-FcγRI mAb (clone 197) in a chronic ITP patient resulted in clinical improvement by preventing FcγRI mediated destruction of IgG-coated platelets [61].

SLE is a non-organ specific autoimmune disease in which IgG autoantibodies are produced against a wide range of self-antigens [56]. One pathogenic factor in SLE is the opsonization of late apoptotic cells by autoantibodies, resulting in decreased FcγRI-mediated clearance of apoptotic cells by phagocytes [62]. IgG autoantibodies may bind to molecules on apoptotic cells that are required

for recognition and facilitation of macrophage uptake, such as phosphatidylserine or C1q [63-65]. Intracellular autoantigens may become exposed, in altered or unaltered form, at the outer surface of apoptotic cells during the apoptotic process [66,67]. Decreased clearance of apoptotic cells results in prolonged exposure of these cell surface-expressed autoantigens to the immune system, which may explain the development of autoantibodies against these intracellular antigens. In part, this is due to increased signaling caused by IgG binding to FcγRs, which may affect the ability of monocyte-derived macrophages to internalize apoptotic cells [62-68]. Fc receptor blockade, with the partial blocking anti-FcγRI antibody 10.1 (see limitations), significantly reduced phagocytosis inhibition [62]. This effect was amplified when anti-FcγRI antibody was combined with anti-FcγRIII blocking antibody (3G8) on macrophages, and it abolished the inhibitory effect of SLE autoantibodies [62].

The formation of ICs between autoantibodies and self-antigens has also been linked to the development of lupus nephritis (LN) [56,69]. In the kidneys, the presence of ICs activates monocytes and macrophages by interacting with FcγRI and FcγRIII, triggering an inflammatory cascade of cytokines and chemokines. Monocytes secrete monocyte chemoattractant protein 1 (MCP-1) [70], which recruits macrophages but may also promote a further influx of monocytes into the kidney. The greater ability of monocytes to migrate and secrete MCP-1 is linked to increased FcγRI expression on the cell surface, especially in LN patients [70], and also with markers of impaired renal function. This could lead to a vicious cycle of renal inflammation and facilitate the infiltration of monocytes to sites of IC deposition in the kidney [71], which eventually could result in permanent tissue damage [72]. FcγRI is critical for the development of LN, as mice with gamma chain-deficient FcγRI forming and depositing ICs were surprisingly protected from severe nephritis [55]. Taken together, these data suggest an important role for FcγRI in the pathogenesis of both SLE and LN and blocking FcγRI seems to increase the clearance of apoptotic cells, but this warrants further research (Figure 3.1 and 3.2).

The most common form of autoimmune inflammatory arthritis is rheumatoid arthritis (RA), which affects up to 1% of the human population [80]. The pathogenesis of RA has been linked to IgG-IC/FcγRI signaling [54,73-75,81] and FcγRI expression levels correlate with disease progression [6]. When compared to total serum IgG1, RA-specific autoantibodies show differences in Fc-linked galactosylation and fucosylation. These IgG1 changes resulted in decreased affinity for FcγRIIIa and FcγRIIb, but not for FcγRI, which could increase the availability of RA-specific autoantibodies to bind and activate FcγRI [82]. In collagen-induced arthritis (CIA) and antigen-induced arthritis (AIA) models, FcγRI-deficient mice showed reduced arthritic symptoms [54,73,81], and treatment with a FcγRI-directed immunotoxin reduced inflammation and bone degradation in human FcγRI–transgenic rats with joint inflammation [83]. In another AIA model, deletion of the FcγRI α-chain was partially protective, but it also impaired their ability to clear infection with *Bordetella pertussis* [6]. Additionally, IgG autoantibody ICs can bind to neutrophils, macrophages, and monocytes, causing pro-inflammatory cytokine release and aggravating inflammation, contributing to RA morbidity. In RA patients, IgG-IC was present in high concentrations in the serum and infected joints, making it an important pathological characteristic of the disease [73,84]. IgG-autoantibodies can directly bind to pre-osteoclasts and induce differentiation, as well as activate mature osteoclasts [57]. Interestingly, in AIA and CIA models, capturing IgG-IC with recombinant soluble FcγRI reduced cartilage degradation [73,74]. Given this, it is of interest to investigate the effect of osteoclast specific anti-FcγRI blocking antibodies in combination with anti-inflammatory treatment options (Figure 3.5).

Besides being a direct target, FcγRI is also widely used as early biomarker for disease detection and prediction of disease outcome for sepsis, HIV, pediatric and adult Crohn's Disease and tuberculosis [85-90]. The FcγRI expression levels were significantly elevated on neutrophils in patients [85-88] and macrophages in *in vivo* models [89]. These data suggest an important role for FcγRI and it could be interesting to examine if blocking FcγRI in these settings could improve the disease outcome.

Neuropathy and pain

Chronic pain is a widespread condition that affects 20% of adults in Western countries [91,92]. Some chronic pain disorders, such as arthritis, are characterized by persistent peripheral nociceptive feedback linked to peripheral inflammation, while others, such as neuropathic pain, are the result of irregular nervous system functioning due to injury or disease [93].

IgG-IC/FcγRI signaling has been linked to both the pathogenesis [54,73,81] and disease-associated pain [8,75,76] in RA. Joint pain is a prominent clinical characteristic of RA, which is caused in part by synovitis and joint destruction [94]. While RA pain is commonly thought to be caused by inflammation, it often continues even after inflammation has been controlled with available therapies, implying the involvement of non-inflammatory mechanisms. FcγRI, but not FcγRII or FcγRIII, has been shown to be expressed in subsets of nociceptive dorsal root ganglion (DRG) neurons in rats and mice [95,96]. Activation of neuronal FcγRI in rat DRG neurons by ICs, raises intracellular calcium levels by activating the

nonselective cation channel TRPC3 through the Syk-PLC-IP3 pathway, thereby increasing neuronal excitability [95,97]. Hence, IgG-IC accumulation in the inflamed joint is sufficient to directly stimulate and sensitize joint sensory neurons through neuronal FcγRI, resulting in joint pain. Direct FcγRI blockade with neutralizing antibodies and FcγRI genetic knockout substantially reduced pain-related behaviors in the AIA mouse model [75,76]. These findings suggest that FcγRI can contribute to arthritis pain through a non-inflammatory mechanism, making it a promising therapeutic target in RA patients with pain refractory to current anti-inflammatory treatments (Figure 3.6).

Tumor targeting with antibodies

Therapeutic mAbs are designed to recognize antigens on tumor cells and mediate anti-tumor effects via various direct Fab-mediated and indirect Fc-mediated mechanisms. Direct mechanisms include inducing receptor internalization and degradation, directly inducing pro-apoptotic signals and blocking the ligand binding site of growth factor receptors [98-100]. Indirect effects include IgG-mediated activation of the classical complement pathway, which results in complement-dependent cytotoxicity (CDC), and FcγR engagement, which results in ADCC of tumor cells [101-103]. The recruitment of cytotoxic effector cells, such as natural killer (NK) cells, monocytes/macrophages, and polymorphonuclear (PMN) cells mediates ADCC. The Fab-arms of mAbs can recognize and bind to only one unique epitope, whereas bispecific antibodies (bsAbs) can simultaneously bind two different and unique antigens, attributing dual functionalities.

Some therapeutic bsAbs were developed to act as a bridge between cytotoxic effector cells expressing FcγRI and tumor-target-overexpressing malignant cells [104,105] (Figure 3.II). FcγRI expression is restricted mainly to cytotoxic immune cells such as monocytes, macrophages, and cytokine stimulated PMNs. As a result, tumor cells bound with bsAbs can be selectively detected by effector cells with cytotoxic potential. Multiple studies have shown the potential of FcγRI in anti-cancer therapy by using bsAbs and fusion proteins to recruit FcγRI on immune cells to tumor-associated-antigens on various tumor cell types including acute myeloid leukemia, acute and chronic myelomonocytic leukemia and melanoma [9,16,79,106,107].

FcγRIs are highly potent triggering molecules to activated PMNs and, in the presence of mAbs that bind FcγRI outside the ligand binding domain, it can mediate lysis of various tumors [104]. A humanized mAb that can bind outside of the Fc-region of FcγRI is H22. As a result, serum IgG has no effect on H22 binding to FcγRI [108]. In the presence of human IgG or serum, bispecific molecules derived from H22 and coupled to tumor-specific antibodies like HER2/neu and TAG-72 or other ligands will trigger lysis of target cells [77-79]. Interestingly, the ADCC activity of the bsAb is significantly higher than that of the mAb alone [78-104]. Experiments in murine tumor models using bsAbs that target tumor cells and FcγRI also demonstrate the potent effector functions of FcγRI [16,104]. In some cases, FcγRI-based bsAb could establish long-term T-cell immunity [104]. Since these bsAbs can bind FcγRI in the presence of saturating concentrations of IgG [16,108], they can effectively exploit the cytotoxic potential of FcγRI under physiological conditions [16,79]. It should be noted that most of these studies into FcγRI bsAbs were performed more than two decades ago. Only recently research into FcγRI targeting has revived, as the role of FcγRI in several diseases is becoming increasingly clear. Moreover, the recent developments regarding designing and producing bsAbs resulted in better and more stable bsAbs [105], making it easier to study FcγRI tumor targeting. After selecting the appropriate tumor target and anti-FcγRI mAb when developing novel bsAbs, they could become valuable tools in effective tumor destruction [77-79,104,109].

Additionally, cytokine stimulation could be a promising addition to anti-tumor therapeutic antibodies to enhance the activity of FcγRI-expressing immune cells (Figure 3.I) [12]. The efficacy of various therapeutic antibodies was increased when combined with cytokine stimulation both *in vitro* and *in vivo* [15,110,111]. Some cytokines, like granulocyte colony-stimulating factor (G-CSF), are associated with increased FcγRI expression on neutrophils and increased recruitment of effector cells [79,112]. However, these processes take several hours or even days. Inside-out signaling of FcγRI to enhance FcγRI-IC binding occurs rapidly, within minutes [14]. Cytokine stimulation combined with antibody therapy may increase the binding capacity of FcγRI-expressing cells to tumor cells immediately after cytokine administration (minutes), while increasing FcγRI expression and recruiting more effector cells from the bone marrow occurs later (hours or days). This may result in more effective anti-tumor responses, especially when timing of cytokine administration correctly. Understanding the regulatory mechanisms of FcγRI activation may aid in the manipulation of immune responses using cytokines during infections, autoimmune diseases, and antibody-based immunotherapy.

Limitations

The use of mAbs directed against the IgG binding site of FcγRI, which block IC binding and subsequent cell activation, is the most direct way to inhibit or modulate FcγRI signaling. Mouse anti-human FcγRI antibodies to inhibit FcγRI ligand binding have been developed [19], but these antibodies may not be FcγRI-specific blocking antibodies as they bind via their Fc domain rather than

their Fab domain or outside of the ligand binding domain of FcγRI [23,75,113,114]. The current commercially available FcγRI blocking antibodies include clones 10.1 (mIgG1), m22 (mIgG1) and 197 (mIgG2a). Clone 10.1 is the most commonly used commercial antibody [19,23], but it is not directly a ligand binding blocking antibody as the binding site of 10.1 is located in EC3 of FcγRI [23], while the IgG binding site is located in EC2 [17] (Figure 2). Our own unpublished data indicates that 10.1 can achieve ~40% IgG blocking at saturating antibody concentrations, indicating it can probably sterically hinder IgG binding to FcγRI to some extent. Hence, there is a need to develop specific FcγRI blocking antibodies. However, this is difficult as the Fc portion of IgG antibodies will readily bind with high affinity to FcγRI, making screening for potential candidates very challenging. To our knowledge, no specific and high-affinity Fab-mediated FcγRI blocking antibodies are currently available. Alternative strategies to block FcγRI are using an IgG Fc-fragment preparation or intravenous administration of pooled human immunoglobulin (IVIg) [52,115]. Indeed, in pediatric ITP patients, IVIg results in rapid recovery of platelet counts [116].

Another promising strategy in autoimmune diseases is to target the ICs rather than FcγRI. Recombinant soluble FcγRs can be used to 'capture' circulating ICs and subsequently prevent binding to surface bound FcγRs (Figure 3.III) [73,74]. Normally, recombinant soluble ectodomains of FcγRI will be expected to be rapidly and fully occupied by circulating IgG. Surprisingly, *in vivo* mouse experiments revealed that soluble FcγRI is effective at alleviating IC-induced inflammation in antibody-dependent models of tissue damage, including CIA [73-74]. The 'on' and 'off' rates of monomeric IgG are fast enough to enable recombinant soluble FcγRI to interact with high concentrations of oligomeric ICs in tissues, which may retain soluble FcγRI locally long enough to effectively inhibit inflammatory cell activation through IC binding to cell surface-bound FcγRI [4]. However, since FcγRI can bind to more than one IgG subclass, it would act more as a universal inhibitor of ICs. Another constraint to use soluble FcγRI is its small molecular size (45 kDa), resulting in fast renal clearance [52]. It also makes it difficult to achieve high enough FcγRI therapeutic concentrations at the site of inflammation to be effective.

The combination of therapeutic antibodies with cytokines has great potential due to the potent pro-inflammatory effects and induction of FcγRI inside-out signaling. However, there are only a few clinical trials currently investigating anti-tumor mAb therapy with cytokines [117-119]. In these studies, there are often no control groups receiving monotherapy (either mAb or cytokine), for good ethical reasons. This does make it difficult to determine the effect of cytokine stimulation on mAb therapy in humans. Nonetheless, the results of these studies are very promising. Adding G-CSF to mAb therapy in relapsed leukemia patients produced good therapy responses for a short duriation [117,118]. Before stem cell transplantation, patients receive anti-thymocyte globulin (ATG), an infusion of horse- or rabbit-derived antibodies against human T cells and the precursor thymocytes that leads to depletion of T-cells by inducing CDC and ADCC. When ATG is combined with G-CSF infusion in these patients, neutrophil-mediated ATG cytotoxicity was significantly higher, thereby enhancing T-cell clearance [120]. Furthermore, the addition of G-CSF to ATG treatment in anemia patients resulted in reduced inflammation and days of hospitalization in the first three months [121], although it does not improve the long-term outcome and sustainability of remission [122].

Directly evaluating the influence of FcγRI inside-out signaling on therapeutic antibody therapy remains challenging, as it is difficult to determine the activation status of FcγRI and the surface expression of FcγRI is often not measured in clinical trials. In addition, inside-out signaling is a rapid process which occurs minutes after cytokine stimulation, while clinical trials usually focus on long term effects of antibody therapy. Nonetheless, the *in vitro* and *in vivo* data on inside-out signaling is very promising in regard to enhancing FcγRI effector functions.

Concluding Remarks & Outlook

Therapeutic antibodies can exploit FcγR-mediated effector functions and targeting FcγRI is a promising strategy to enhance the efficacy of antibody-based therapy (Figure 3). FcγRI plays an important role in mAb based therapy [5,7,12], and through antibody engineering, activating or inhibitory immunomodulatory effector functions of FcγRI can be initiated [16,77-79,104]. Moreover, in various autoimmune diseases, antigens and autoantibodies cross-link and form ICs that bind and activate FcγRI [55]. These inflammatory effector functions can cause extensive tissue damage in diseases like RA and SLE, but also chronic joint pain [75,76]. In these autoimmune diseases, blocking IC-FcγRI interactions with mAbs that specifically block the ligand binding domain of FcγRI may be beneficial.

Using anti-FcγRI / anti-tumor bsAbs is an attractive alternative to conventional mAbs for direct tumor killing as they exhibit dual specificity for the target and effector cells. They can be designed to recruit a range of cellular effectors, like T cells and NK cells [104,105]. If these bsAbs bind an epitope outside of the ligand binding domain of FcγRI, there is no competition with human IgG, thus ADCC activity can be attained under normal serum conditions [16,79]. Additionally, this design would make it possible for IgG to still mediate its function by binding with its Fc-tail to FcγRI [16]. Together, these bsAbs can result in optimal tumor killing.

In conclusion, the involvement of FcγRI in many inflammatory diseases makes FcγRI a promising target in treatment of autoimmune and malignant diseases. A better understanding of inside-out signaling in combination with antibody therapy will lead to better and safer therapies.

Conflicts of Interest

The authors have no conflicts of interest to disclose.

Acknowledgements

Illustrations were created with BioRender.com.

References

1. Nimmerjahn F, Ravetch JV. Fcγ receptors as regulators of immune responses. Nature Reviews Immunology. 2008 Jan;8(1):34-47.

2. Takai T. Fc receptors and their role in immune regulation and autoimmunity. Journal of Clinical Immunology. 2005 Jan 1;25(1):1-8.

3. Groselj-Grenc M, Ihan A, Derganc M. Neutrophil and monocyte CD64 and CD163 expression in critically ill neonates and children with sepsis: comparison of fluorescence intensities and calculated indexes. Mediators of Inflammation. 2008 Oct;2008.

4. Bruhns P, Iannascoli B, England P, Mancardi DA, Fernandez N, Jorieux S, et al. Specificity and affinity of human Fcγ receptors and their polymorphic variants for human IgG subclasses. Blood, The Journal of the American Society of Hematology. 2009 Apr 16;113(16):3716-25.

5. Barnes N, Gavin AL, Tan PS, Mottram P, Koentgen F, Hogarth PM. FcγRI-deficient mice show multiple alterations to inflammatory and immune responses. Immunity. 2002 Mar 1;16(3):379-89.

6. Ioan-Facsinay A, De Kimpe SJ, Hellwig SM, Van Lent PL, Hofhuis FM, Van Ojik HH, et al. FcγRI (CD64) contributes substantially to severity of arthritis, hypersensitivity responses, and protection from bacterial infection. Immunity. 2002 Mar 1;16(3):391-402.

7. Bevaart L, Jansen MJ, van Vugt MJ, Verbeek JS, van de Winkel JG, Leusen JH. The high-affinity IgG receptor, FcγRI, plays a central role in antibody therapy of experimental melanoma. Cancer Research. 2006 Feb 1;66(3):1261-4.

8. Liang Y, Zhang Z, Juan Z, Zhang R, Zhang C. The high-affinity IgG receptor FcγRI modulates peripheral nerve injury-induced neuropathic pain in rats. Molecular Brain. 2019 Dec;12(1):1-4.

9. Boross P, Jansen JM, van Tetering G, Nederend M, Brandsma A, Meyer S, et al. Anti-tumor activity of human IgG1 anti-gp75 TA99 mAb against B16F10 melanoma in human FcgammaRI transgenic mice. Immunology Letters. 2014 Aug 1;160(2):151-7.

10. Van Der Poel CE, Karssemeijer RA, Boross P, Van Der Linden JA, Blokland M, Van De Winkel JG, et al. Cytokine-induced immune complex binding to the high-affinity IgG receptor, FcγRI, in the presence of monomeric IgG. Blood, The Journal of the American Society of Hematology. 2010 Dec 9;116(24):5327-33.

11. Springer TA, Dustin ML. Integrin inside-out signaling and the immunological synapse. Current Opinion in Cell Biology. 2012 Feb 1;24(1):107-15.

12. Brandsma AM, Jacobino SR, Meyer S, ten Broeke T, Leusen JH. Fc receptor inside-out signaling and possible impact on antibody therapy. Immunological Reviews. 2015 Nov;268(1):74-87.

13. Bakema JE, Bakker A, de Haij S, Honing H, Bracke M, Koenderman L, et al. Inside-out regulation of FcαRI (CD89) depends on PP2A. The Journal of Immunology. 2008 Sep 15;181(6):4080-8.

14. Brandsma AM, Schwartz SL, Wester MJ, Valley CC, Blezer GL, Vidarsson G, et al. Mechanisms of inside-out signaling of the high-affinity IgG receptor FcγRI. Science Signaling. 2018 Jul 24;11(540).

15. Valerius T, Repp R, De Wit TP, Berthold S, Platzer E, Kalden JR, et al. Involvement of the high-affinity receptor for IgG (Fc gamma RI; CD64) in enhanced tumor cell cytotoxicity of neutrophils during granulocyte colony-stimulating factor therapy. Blood.1993 Aug;82(3):931-9.

16. Heijnen IA, Rijks LJ, Schiel A, Stockmeyer B, Van Ojik HH, Dechant M, et al. Generation of HER-2/neu-specific cytotoxic neutrophils in vivo: efficient arming of neutrophils by combined administration of granulocyte colony-stimulating factor and Fcgamma receptor I bispecific antibodies. The Journal of Immunology. 1997 Dec 1;159(11):5629-39.

17. Kiyoshi M, Caaveiro JM, Kawai T, Tashiro S, Ide T, Asaoka Y, et al. Structural basis for binding of human IgG1 to its high-affinity human receptor FcγRI. Nature Communications. 2015 Apr 30;6(1):1-1.

18. Temming AR, Bentlage AE, de Taeye SW, Bosman GP, Lissenberg-Thunnissen SN, Derksen NI, et al. Cross-reactivity of mouse IgG subclasses to human Fc gamma receptors: Antibody deglycosylation only eliminates IgG2b binding. Molecular Immunology. 2020 Nov 1;127:79-86.

19. Dougherty GJ, Selvendran Y, Murdoch S, Palmer DG, Hogg N. The human mononuclear phagocyte high-affinity Fc receptor, FcRI, defined by a monoclonal antibody, 10.1. European Journal of Immunology. 1987;17(10):1453-9.

20. Mancardi DA, Albanesi M, Jönsson F, Iannascoli B, Van Rooijen N, Kang X, et al. The high-affinity human IgG receptor FcγRI (CD64) promotes IgG-mediated inflammation, anaphylaxis, and antitumor immunotherapy. Blood, The Journal of the American Society of Hematology. 2013 Feb 28;121(9):1563-73.

21. Bruhns P. Properties of mouse and human IgG receptors and their contribution to disease models. Blood, The Journal of the American Society of Hematology. 2012 Jun 14;119(24):5640-9.

22. Dekkers G, Bentlage AE, Stegmann TC, Howie HL, Lissenberg-Thunnissen S, Zimring J, et al. Affinity of human IgG subclasses to mouse Fc gamma receptors. InMAbs 2017 Jul 4 (Vol. 9, No. 5, pp. 767-773). Taylor & Francis.

23. Harrison PT, Allen JM. High affinity IgG binding by FcgammaRI (CD64) is modulated by two distinct IgSF domains and the transmembrane domain of the receptor. Protein Engineering. 1998 Mar 1;11(3):225-32.

24. Duncan AR, Woof JM, Partridge LJ, Burton DR, Winter G. Localization of the binding site for the human high-affinity Fc receptor on IgG. Nature. 1988 Apr;332(6164):563-4.

25. Chappel MS, Isenman DE, Everett M, Xu YY, Dorrington KJ, Klein MH. Identification of the Fc gamma receptor class I binding site in human IgG through the use of recombinant IgG1/IgG2 hybrid and point-mutated antibodies. Proceedings of the National Academy of Sciences. 1991 Oct 15;88(20):9036-40.

26. Lu J, Ellsworth JL, Hamacher N, Oak SW, Sun PD. Crystal structure of Fcγ receptor I and its implication in high affinity γ-immunoglobulin binding. Journal of Biological Chemistry. 2011 Nov 25;286(47):40608-13.

27. Lu J, Chu J, Zou Z, Hamacher NB, Rixon MW, Sun PD. Structure of FcγRI in complex with Fc reveals the importance of glycan recognition for high-affinity IgG binding. Proceedings of the National Academy of Sciences. 2015 Jan 20;112(3):833-8.

28. Duchemin AM, Ernst LK, Anderson CL. Clustering of the high affinity Fc receptor for immunoglobulin G (Fc gamma RI) results in phosphorylation of its associated gamma-chain. Journal of Biological Chemistry. 1994 Apr 22;269(16):12111-7.

29. Harrison PT, Davis W, Norman JC, Hockaday AR, Allen JM. Binding of monomeric immunoglobulin G triggers Fc gamma RI-mediated endocytosis. Journal of Biological Chemistry. 1994 Sep 30;269(39):24396-402.

30. Lux A, Yu X, Scanlan CN, Nimmerjahn F. Impact of immune complex size and glycosylation on IgG binding to human FcγRs. The Journal of Immunology. 2013 Apr 15;190(8):4315-23.

31. van Vugt MJ, Kleijmeer MJ, Keler T, Zeelenberg I, van Dijk MA, Leusen JH, et al. The FcγRIa (CD64) ligand binding chain triggers major histocompatibility complex class II antigen presentation independently of its associated FcR γ-chain. Blood, The Journal of the American Society of Hematology. 1999 Jul 15;94(2):808-17.

32. Pan LF, Kreisle RA, Shi YD. Detection of Fcγ receptors on human endothelial cells stimulated with cytokines tumour necrosis factor-alpha (TNF-α) and interferon-gamma (IFN-γ). Clinical and Experimental Immunology. 1998 Jun;112(3):533.

33. Okun E, Mattson MP, Arumugam TV. Involvement of Fc receptors in disorders of the central nervous system. Neuromolecular Medicine. 2010 Jun 1;12(2):164-78.

34. Fanger NA, Voigtlaender D, Liu C, Swink S, Wardwell K, Fisher J, et al. Characterization of expression, cytokine regulation, and effector function of the high affinity IgG receptor Fc gamma RI (CD64) expressed on human blood dendritic cells. The Journal of Immunology. 1997 Apr 1;158(7):3090-8.

35. Albanesi M, Mancardi DA, Macdonald LE, Iannascoli B, Zitvogel L, Murphy AJ, Leusen JH, Bruhns P. Cutting edge: FcγRIII (CD16) and FcγRI (CD64) are responsible for anti-glycoprotein 75 monoclonal antibody TA99 therapy for experimental metastatic B16 melanoma. The Journal of Immunology. 2012 Dec 15;189(12):5513-7.

36. Getahun A, Cambier JC. Of ITIM s, ITAM s, and ITAM is: revisiting immunoglobulin Fc receptor signaling. Immunological Reviews. 2015 Nov;268(1):66-73.

37. Nimmerjahn F, Ravetch JV. Fc-receptors as regulators of immunity. Advances in immunology. 2007 Jan 1;96:179-204.

38. Huang ZY, Hunter S, Kim MK, Indik ZK, Schreiber AD. The effect of phosphatases SHP-1 and SHIP-1 on signaling by the ITIM-and ITAM-containing Fcγ receptors FcγRIIB and FcγRIIA. Journal of Leukocyte Biology. 2003 Jun;73(6):823-9.

39. Cady CT, Powell MS, Harbeck RJ, Giclas PC, Murphy

JR, Katial RK, et al. IgG antibodies produced during subcutaneous allergen immunotherapy mediate inhibition of basophil activation via a mechanism involving both FcγRIIA and FcγRIIB. Immunology Letters. 2010 May 4;130(1-2):57-65.

40. Sutterwala FS, Noel GJ, Salgame P, Mosser DM. Reversal of proinflammatory responses by ligating the macrophage Fcγ receptor type I. The Journal of Experimental Medicine. 1998 Jul 1;188(1):217-22.

41. Rodriguez W, Mold C, Kataranovski M, Hutt JA, Marnell LL, Verbeek JS, et al. C-reactive protein-mediated suppression of nephrotoxic nephritis: role of macrophages, complement, and Fcγ receptors. The Journal of Immunology. 2007 Jan 1;178(1):530-8.

42. Blank U, Launay P, Benhamou M, Monteiro RC. Inhibitory ITAMs as novel regulators of immunity. Immunological Reviews. 2009 Nov;232(1):59-71.

43. Swisher JF, Feldman GM. The many faces of FcγRI: implications for therapeutic antibody function. Immunological Reviews. 2015 Nov;268(1):160-74.

44. Boekhoudt GH, Frazier-Jessen MR, Feldman GM. Immune complexes suppress IFN-γ signaling by activation of the FcγRI pathway. Journal of Leukocyte Biology. 2007 Apr;81(4):1086-92.

45. van Vugt MJ, Heijnen IA, Capel PJ, Park SY, Ra C, Saito T, et al. FcR gamma-chain is essential for both surface expression and function of human Fc gamma RI (CD64) in vivo.

46. Beekman JM, van der Linden JA, van de Winkel JG, Leusen JH. FcγRI (CD64) resides constitutively in lipid rafts. Immunology Letters. 2008 Mar 15;116(2):149-55.

47. van der Poel CE, Spaapen RM, van de Winkel JG, Leusen JH. Functional characteristics of the high affinity IgG receptor, FcγRI. The Journal of Immunology. 2011 Mar 1;186(5):2699-704.

48. Edberg JC, Qin H, Gibson AW, Yee AM, Redecha PB, Indik ZK, et al. The CY domain of the FcγRIa α-chain (CD64) alters γ-chain tyrosine-based signaling and phagocytosis. Journal of Biological Chemistry. 2002 Oct 25;277(43):41287-93.

49. Haystead TA, Sim AT, Carling D, Honnor RC, Tsukitani Y, Cohen P, et al. Effects of the tumour promoter okadaic acid on intracellular protein phosphorylation and metabolism. Nature. 1989 Jan;337(6202):78-81.

50. Bissantz C. Conformational changes of G protein-coupled receptors during their activation by agonist binding. Journal of Receptors and Signal Transduction. 2003 Jan 1;23(2-3):123-53.

51. Koenderman L. Inside-out control of Fc-receptors. Frontiers in Immunology. 2019 Mar 21;10:544.

52. Hogarth PM, Pietersz GA. Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond. Nature Reviews Drug discovery. 2012 Apr;11(4):311-31.

53. van den Berg WB, Arandhara VL, Sjef J, van der Kaa MH, Claassens JW. Destructive Arthritis in the Absence of Both. J Immunol. 2008;180:5083-91.

54. Van Lent PL, Nabbe K, Blom AB, Holthuysen AE, Sloetjes A, Van De Putte LB, et al. Role of activatory FcγRI and FcγRIII and inhibitory FcγRII in inflammation and cartilage destruction during experimental antigen-induced arthritis. The American Journal of Pathology. 2001 Dec 1;159(6):2309-20.

55. Clynes R, Dumitru C, Ravetch JV. Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis. Science. 1998 Feb 13;279(5353):1052-4.

56. McLigeyo SO. Pathogenesis of lupus nephritis: a review. East African Medical Journal. 1998 Nov 1;75(11):628-31.

57. Di Ceglie I, Kruisbergen NN, van den Bosch MH, van Lent PL. Fc-gamma receptors and S100A8/A9 cause bone erosion during rheumatoid arthritis. Do they act as partners in crime?. Rheumatology. 2019 Aug 1;58(8):1331-43.

58. Akinrinmade OA, Chetty S, Daramola AK, Islam MU, Thepen T, Barth S. CD64: an attractive immunotherapeutic target for M1-type macrophage mediated chronic inflammatory diseases. Biomedicines. 2017 Sep;5(3):56.

59. Hristodorov D, Mladenov R, von Felbert V, Huhn M, Fischer R, Barth S, et al. Targeting CD64 mediates elimination of M1 but not M2 macrophages in vitro and in cutaneous inflammation in mice and patient biopsies. InMAbs 2015 Sep 3 (Vol. 7, No. 5, pp. 853-862). Taylor & Francis.

60. Kiekens RC, Thepen T, Bihari IC, Knol EF, Van De Winkel JG, Bruijnzeel-Koomen CA. Expression of Fc receptors for IgG during acute and chronic cutaneous inflammation in atopic dermatitis. British Journal of Dermatology. 2000 Jun;142(6):1106-13.

61. Ericson SG, Coleman KD, Wardwell K, Baker S, Fanger MW, Guyre PM, et al. Monoclonal antibody

197 (anti-FcγRI) infusion in a patient with immune thrombocytopenia purpura (ITP) results in down-modulation of FcγRI on circulating monocytes. British Journal of Haematology. 1996 Feb;92(3):718-24.

62. Reefman E, Horst G, Nijk MT, Limburg PC, Kallenberg CG, Bijl M. Opsonization of late apoptotic cells by systemic lupus erythematosus autoantibodies inhibits their uptake via an Fcγ receptor–dependent mechanism. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology. 2007 Oct;56(10):3399-411.

63. Li MO, Sarkisian MR, Mehal WZ, Rakic P, Flavell RA. Phosphatidylserine receptor is required for clearance of apoptotic cells. Science. 2003 Nov 28;302(5650):1560-3.

64. Toschi V, Motta A, Castelli C, Gibelli S, Cimminiello C, Molaro GL, et al. Prevalence and clinical significance of antiphospholipid antibodies to noncardiolipin antigens in systemic lupus erythematosus. Pathophysiology of Haemostasis and Thrombosis. 1993;23(5):275-83.

65. Korb LC, Ahearn JM. C1q binds directly and specifically to surface blebs of apoptotic human keratinocytes: complement deficiency and systemic lupus erythematosus revisited. The Journal of Immunology. 1997 May 15;158(10):4525-8.

66. Utz PJ, Hottelet M, Schur PH, Anderson P. Proteins phosphorylated during stress-induced apoptosis are common targets for autoantibody production in patients with systemic lupus erythematosus. The Journal of Experimental Medicine. 1997 Mar 3;185(5):843-54.

67. Utz PJ, Anderson P. Posttranslational protein modifications, apoptosis, and the bypass of tolerance to autoantigens. Arthritis & Rheumatism. 1998 Jul;41(7):1152-60.

68. Erwig LP, Gordon S, Walsh GM, Rees AJ. Previous uptake of apoptotic neutrophils or ligation of integrin receptors downmodulates the ability of macrophages to ingest apoptotic neutrophils. Blood, The Journal of the American Society of Hematology. 1999 Feb 15;93(4):1406-12.

69. Lukacs K, Kavai M, Banyai A, Sonkoly I, Vegh E, Szabo G, et al. Effects of immune complexes from SLE patients on human monocyte locomotion and Fc receptor function. Annals of the Rheumatic Diseases. 1984 Oct 1;43(5):729-33.

70. Li Y, Lee PY, Sobel ES, Narain S, Satoh M, Segal MS, et al. Increased expression of FcγRI/CD64 on circulating monocytes parallels ongoing inflammation and nephritis in lupus. Arthritis Research & Therapy. 2009 Feb;11(1):1-3.

71. Heller T, Gessner JE, Schmidt RE, Klos A, Bautsch W, Köhl J. Cutting edge: Fc receptor type I for IgG on macrophages and complement mediate the inflammatory response in immune complex peritonitis. The Journal of Immunology. 1999 May 15;162(10):5657-61.

72. Li Y, Tucci M, Narain S, Barnes EV, Sobel ES, Segal MS, et al. Urinary biomarkers in lupus nephritis. Autoimmunity Reviews. 2006 Jul 1;5(6):383-8.

73. Ellsworth JL, Hamacher N, Harder B, Bannink K, Bukowski TR, Byrnes-Blake K, et al. Recombinant soluble human FcγR1A (CD64A) reduces inflammation in murine collagen-induced arthritis. The Journal of Immunology. 2009 Jun 1;182(11):7272-9.

74. Ellsworth JL, Maurer M, Harder B, Hamacher N, Lantry M, Lewis KB, et al. Targeting immune complex-mediated hypersensitivity with recombinant soluble human FcγRIA (CD64A). The Journal of Immunology. 2008 Jan 1;180(1):580-9.

75. Wang L, Jiang X, Zheng Q, Jeon SM, Chen T, Liu Y, et al. Neuronal FcγRI mediates acute and chronic joint pain. The Journal of Clinical Investigation. 2019 Sep 3;129(9):3754-69.

76. Liu F, Shen X, Su S, Cui H, Fang Y, Wang T, et al. Fcγ Receptor I–Coupled Signaling in Peripheral Nociceptors Mediates Joint Pain in a Rat Model of Rheumatoid Arthritis. Arthritis & Rheumatology. 2020 Oct;72(10):1668-78.

77. Goldstein J, Graziano RF, Sundarapandiyan K, Somasundaram C, Deo YM. Cytolytic and cytostatic properties of an anti-human Fc gammaRI (CD64) x epidermal growth factor bispecific fusion protein. The Journal of Immunology. 1997 Jan 15;158(2):872-9.

78. Russoniello C, Somasundaram C, Schlom J, Deo YM, Keler T. Characterization of a novel bispecific antibody that mediates Fcgamma receptor type I-dependent killing of tumor-associated glycoprotein-72-expressing tumor cells. Clinical Cancer Research. 1998 Sep 1;4(9):2237-43.

79. Keler T, Graziano RF, Mandal A, Wallace PK, Fisher J, Guyre PM, et al. Bispecific antibody-dependent cellular cytotoxicity of HER2/neu-overexpressing tumor cells by Fcγ receptor type I-expressing effector cells. Cancer Research. 1997 Sep 15;57(18):4008-14.

80. Almutairi K, Nossent J, Preen D, Keen H, Inderjeeth C. The global prevalence of rheumatoid arthritis: a meta-analysis based on a systematic review. Rheumatology International. 2021 May;41(5):863-77.

81. Lent PL, Grevers L, Lubberts E, Vries TJ, Nabbe KC, Verbeek S, et al. Fcγ receptors directly mediate cartilage,

but not bone, destruction in murine antigen-induced arthritis: Uncoupling of cartilage damage from bone erosion and joint inflammation. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology. 2006 Dec;54(12):3868-77.

82. Rombouts Y, Ewing E, van de Stadt LA, Selman MH, Trouw LA, Deelder AM, et al. Anti-citrullinated protein antibodies acquire a pro-inflammatory Fc glycosylation phenotype prior to the onset of rheumatoid arthritis. Annals of the Rheumatic Diseases. 2015 Jan 1;74(1):234-41.

83. van Vuuren AJ, van Roon JA, Walraven V, Stuij I, Harmsen MC, McLaughlin PM, et al. CD64-directed immunotoxin inhibits arthritis in a novel CD64 transgenic rat model. The Journal of Immunology. 2006 May 15;176(10):5833-8.

84. Grevers LC, de Vries TJ, Everts V, Verbeek JS, van den Berg WB, van Lent PL. Immune complex-induced inhibition of osteoclastogenesis is mediated via activating but not inhibitory Fcγ receptors on myeloid precursor cells. Annals of the Rheumatic Diseases. 2013 Feb 1;72(2):278-85.

85. Therrien A, Chapuy L, Bsat M, Rubio M, Bernard G, Arslanian E, et al. Recruitment of activated neutrophils correlates with disease severity in adult Crohn's disease. Clinical & Experimental Immunology. 2019 Feb;195(2):251-64.

86. Minar P, Jackson K, Tsai YT, Sucharew H, Rosen MJ, Denson LA. Validation of neutrophil CD64 blood biomarkers to detect mucosal inflammation in pediatric Crohn's disease. Inflammatory Bowel Diseases. 2018 Jan 1;24(1):198-208.

87. Wang X, Li ZY, Zeng L, Zhang AQ, Pan W, Gu W, et al. Neutrophil CD64 expression as a diagnostic marker for sepsis in adult patients: a meta-analysis. Critical Care. 2015 Dec;19(1):1-9.

88. Hoffmann JJ. Neutrophil CD64: a diagnostic marker for infection and sepsis. Clinical Chemistry and Laboratory Medicine. 2009 Aug 1;47(8):903-16.

89. Montefiori DC, Interrante MV, Bell BN, Rubio AA, Joyce JG, Shiver JW, et al. The high-affinity immunoglobulin receptor FcγRI potentiates HIV-1 neutralization via antibodies against the gp41 N-heptad repeat. Proceedings of the National Academy of Sciences. 2021 Jan 19;118(3).

90. Corrêa RD, Rodrigues LS, Pereira LH, Nogueira OC, Leung J, Sousa MD, et al. Neutrophil CD64 expression levels in IGRA-positive individuals distinguish latent tuberculosis from active disease. Memórias do Instituto Oswaldo Cruz. 2019 Apr 8;114.

91. Breivik H, Eisenberg E, O'Brien T. The individual and societal burden of chronic pain in Europe: the case for strategic prioritisation and action to improve knowledge and availability of appropriate care. BMC Public Health. 2013 Dec;13(1):1-4.

92. Dahlhamer J, Lucas J, Zelaya C, Nahin R, Mackey S, DeBar L, et al. Prevalence of chronic pain and high-impact chronic pain among adults—United States, 2016. Morbidity and Mortality Weekly Report. 2018 Sep 14;67(36):1001.

93. Grace PM, Tawfik VL, Svensson CI, Burton MD, Loggia ML, Hutchinson MR. The neuroimmunology of chronic pain: from rodents to humans. Journal of Neuroscience. 2021 Feb 3;41(5):855-65.

94. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. New England Journal of Medicine. 2011 Dec 8;365(23):2205-19.

95. Qu L, Zhang P, LaMotte RH, Ma C. Neuronal Fc-gamma receptor I mediated excitatory effects of IgG immune complex on rat dorsal root ganglion neurons. Brain, Behavior, and Immunity. 2011 Oct 1;25(7):1399-407.

96. Andoh T, Kuraishi Y. Direct action of immunoglobulin G on primary sensory neurons through Fc gamma receptor I. The FASEB Journal. 2004 Jan;18(1):182-4.

97. Qu L, Li Y, Pan X, Zhang P, LaMotte RH, Ma C. Transient receptor potential canonical 3 (TRPC3) is required for IgG immune complex-induced excitation of the rat dorsal root ganglion neurons. Journal of Neuroscience. 2012 Jul 11;32(28):9554-62.

98. Reslan L, Dalle S, Herveau S, Perrial E, Dumontet C. Apoptotic induction by anti-CD20 antibodies in chronic lymphocytic leukemia: comparison of rituximab and obinutuzumab. Leukemia & Lymphoma. 2014 Jan 1;55(1):188-90.

99. Klapper LN, Waterman H, Sela M, Yarden Y. Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2. Cancer Research. 2000 Jul 1;60(13):3384-8.

100. Goldstein NI, Prewett M, Zuklys K, Rockwell P, Mendelsohn J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clinical Cancer Research. 1995 Nov 1;1(11):1311-8.

101. Shuptrine CW, Surana R, Weiner LM. Monoclonal antibodies for the treatment of cancer. InSeminars in Cancer Biology 2012 Feb 1 (Vol. 22, No. 1, pp. 3-13). Academic Press.

102. Bindon CI, Hale G, Brüggemann M, Waldmann HE. Human monoclonal IgG isotypes differ in complement activating function at the level of C4 as well as C1q. Journal of Experimental Medicine. 1988 Jul 1;168(1):127-42.

103. Meyer S, Leusen JH, Boross P. Regulation of complement and modulation of its activity in monoclonal antibody therapy of cancer. InMAbs 2014 Sep 3 (Vol. 6, No. 5, pp. 1133-1144). Taylor & Francis.

104. Honeychurch J, Tutt AL, Valerius T, Heijnen IA, Van de Winkel JG, Glennie MJ. Therapeutic efficacy of FcγRI/CD64-directed bispecific antibodies in B-cell lymphoma. Blood, The Journal of the American Society of Hematology. 2000 Nov 15;96(10):3544-52.

105. Klein C, Schaefer W, Regula JT. The use of CrossMAb technology for the generation of bi-and multispecific antibodies. InMAbs 2016 Aug 17 (Vol. 8, No. 6, pp. 1010-1020). Taylor & Francis.

106. Akinrinmade OA, Jordaan S, Hristodorov D, Mladenov R, Mungra N, Chetty S, et al. Human MAP tau based targeted cytolytic fusion proteins. Biomedicines. 2017 Sep;5(3):36.

107. Mladenov R, Hristodorov D, Cremer C, Gresch G, Grieger E, Schenke L, et al. CD64-directed microtubule associated protein tau kills leukemic blasts ex vivo. Oncotarget. 2016 Oct 11;7(41):67166.

108. Graziano RF, Tempest PR, White P, Keler T, Deo Y, Ghebremariam H, et al. Construction and characterization of a humanized anti-gamma-Ig receptor type I (Fc gamma RI) monoclonal antibody. The Journal of Immunology. 1995 Nov 15;155(10):4996-5002.

109. Bevaart L, Goldstein J, Vitale L, Russoniello C, Treml J, Zhang J, et al. Direct targeting of genetically modified tumour cells to FcγRI triggers potent tumour cytotoxicity. British Journal of Haematology. 2006 Feb;132(3):317-25.

110. Kushner BH, Cheung NK. GM-CSF enhances 3F8 monoclonal antibody-dependent cellular cytotoxicity against human melanoma and neuroblastoma. Blood. 1989 May 15;73(7):1936-41.

111. Molfetta R, Quatrini L, Gasparrini F, Zitti B, Santoni A, Paolini R. Regulation of fc receptor endocytic trafficking by ubiquitination. Frontiers in Immunology. 2014 Sep 18;5:449.

112. Würflein D, Dechant M, Stockmeyer B, Tutt AL, Hu P, Repp R, et al. Evaluating antibodies for their capacity to induce cell-mediated lysis of malignant B cells. Cancer Research. 1998 Jul 15;58(14):3051-8.

113. Unkeless JC. Characterization of a monoclonal antibody directed against mouse macrophage and lymphocyte Fc receptors. The Journal of Experimental Medicine. 1979 Sep 19;150(3):580-96.

114. Guyre PM, Graziano RF, Vance BA, Morganelli PM, Fanger MW. Monoclonal antibodies that bind to distinct epitopes on Fc gamma RI are able to trigger receptor function. The Journal of Immunology. 1989 Sep 1;143(5):1650-5.

115. Nagelkerke SQ, Dekkers G, Kustiawan I, van de Bovenkamp FS, Geissler J, Plomp R, et al. Inhibition of FcγR-mediated phagocytosis by IVIg is independent of IgG-Fc sialylation and FcγRIIb in human macrophages. Blood, The Journal of the American Society of Hematology. 2014 Dec 11;124(25):3709-18.

116. Debre M, Griscelli C, Bonnet MC, Carosella E, Philippe N, Reinert P, et al. Infusion of Fcγ fragments for treatment of children with acute immune thrombocytopenic purpura. The Lancet. 1993 Oct 16;342(8877):945-9.

117. Van der Kolk LE, Grillo-Lopez AJ, Baars JW, Van Oers MH. Treatment of relapsed B-cell non-Hodgkin's lymphoma with a combination of chimeric anti-CD20 monoclonal antibodies (rituximab) and G-CSF: final report on safety and efficacy. Leukemia. 2003 Aug;17(8):1658-64.

118. Gorin NC, Isnard F, Garderet L, Ikhlef S, Corm S, Quesnel B, et al. Administration of alemtuzumab and G-CSF to adults with relapsed or refractory acute lymphoblastic leukemia: results of a phase II study. European journal of haematology. 2013 Oct;91(4):315-21.

119. Cohen JB, Bucur S, Winton EF, Sinha R, Heffner LT, King N, et al. Combination of GM-CSF with fludarabine-containing regimens in chronic lymphocytic leukemia and indolent non-Hodgkin lymphoma. Clinical Lymphoma Myeloma and Leukemia. 2015 Sep 1;15(9):514-8.

120. de Koning C, Gabelich JA, Langenhorst J, Admiraal R, Kuball J, Boelens JJ, et al. Filgrastim enhances T-cell clearance by antithymocyte globulin exposure after unrelated cord blood transplantation. Blood Advances. 2018 Mar 13;2(5):565-74.

121. Tichelli A, Schrezenmeier H, Socié G, Marsh J, Bacigalupo A, Dührsen U, et al. A randomized controlled study in patients with newly diagnosed severe aplastic anemia receiving antithymocyte globulin (ATG),

cyclosporine, with or without G-CSF: a study of the SAA Working Party of the European Group for Blood and Marrow Transplantation. Blood, The Journal of the American Society of Hematology. 2011 Apr 28;117(17):4434-41.

122. Tichelli A, De Latour RP, Passweg J, Knol-Bout C, Socié G, Marsh J, et al. Long-term outcome of a randomized controlled study in patients with newly diagnosed severe aplastic anemia treated with antithymocyte globulin and cyclosporine, with or without granulocyte colony-stimulating factor: a Severe Aplastic Anemia Working Party Trial from the European Group of Blood and Marrow Transplantation. Haematologica. 2020 May;105(5):1223-1231.